Your browser doesn't support javascript.
loading
Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy.
Razaghi, Ali; Durand-Dubief, Mickaël; Brusselaers, Nele; Björnstedt, Mikael.
Affiliation
  • Razaghi A; Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Durand-Dubief M; Discovery & Front-End Innovation, Lesaffre Institute of Science & Technology, Lesaffre International, Marcq-en-Baroeul, France.
  • Brusselaers N; Global Health Institute, Antwerp University, Antwerp, Belgium.
  • Björnstedt M; Centre for Translational Microbiome Research (CTMR), Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.
Front Immunol ; 14: 1249330, 2023.
Article in En | MEDLINE | ID: mdl-37691915
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interferon Type I / Melanoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interferon Type I / Melanoma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Country of publication: